2024年10月的前两周，全球医药市场共签署了36项资产授权和合作协议。中国市场达成10项交易，包括6项出海交易、1项引进交易和3项国内交易。
中国市场最引人注目的出海交易是阿斯利康与石药集团就心血管资产YS2302018达成的授权交易，首付1亿美元，总价值20.2亿美元。唯一的一项引进交易是普米斯就Talem Therapeutics临床前肿瘤资产TATX-20达成的许可交易。最领先的国内交易是正大天晴引进友芝友生物临床三期资产M701，总价值1.41亿美元。
国际市场上，共签署了26项资产授权和合作协议。最大的一笔交易是Recordati收购赛诺菲已上市药物sutimlimab，首付款8.5亿美元，总价值11亿美元。
In the first two weeks of October, a total of 36 licensing and cooperation deals were signed globally. Within China’s biotech industry, 6 out-licensing deals, 1 in-licensing deal, and 3 domestic deals were finalized. The largest out-licensing deal involved CSPC Pharma and AstraZeneca, with a total deal value of $2.02 billion, including a $100 million upfront payment for the cardiovascular asset YS2302018. The sole in-licensing deal was between Talem Therapeutics and Biotheus for the pre-clinical oncology asset TATX-20. Meanwhile, the leading domestic deal was signed between YZY Biopharma and Chia Tai TianqingPharmaceutical for the Phase III asset M701, valued at $141 million.
Globally, 26 licensing and cooperation deals were completed. The top deal was an asset acquisition between Sanofi and Recordati for the approved asset sutimlimab, with a total deal value of $1.1 billion, including an upfront payment of $850 million.
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit www.yafocapital.com
Event Name:
